Novel opportunities for next-generation probiotics targeting metabolic syndrome

Current Opinion in Biotechnology

Volumn 32, Issue , 2015, Pages 21-27

  Cani, Patrice D ^a   Van Hul, Matthias ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PATIENT TREATMENT;

BENEFICIAL EFFECTS; DIABETIC PATIENT; GASTROINTESTINAL TRACT; METABOLIC PROFILES; METABOLIC SYNDROMES; MICROBIOTAS; PROBIOTIC STRAIN; PROBIOTICS;

METABOLISM;

GLUCOSE; HYDROLASE; LIPOPOLYSACCHARIDE; PROBIOTIC AGENT; AMIDASE; CHOLOYLGLYCINE HYDROLASE;

AKKERMANSIA MUCINIPHILA; BACTERIAL STRAIN; BIFIDOBACTERIUM; DISEASE ASSOCIATION; DRUG MECHANISM; ENZYME ACTIVITY; FAT MASS; GLUCOSE BLOOD LEVEL; HOST PATHOGEN INTERACTION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REGULATORY MECHANISM; REVIEW; SACCHAROMYCES BOULARDII; SACCHAROMYCES CEREVISIAE; VERRUCOMICROBIA; ANIMAL; DIET THERAPY; INTESTINE MUCOSA; METABOLISM;

AMIDOHYDROLASES; ANIMALS; BIFIDOBACTERIUM; HUMANS; INTESTINAL MUCOSA; LACTOBACILLUS; METABOLIC SYNDROME X; PROBIOTICS;

EID: 84910614571     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2014.10.006     Document Type: Review

References (65)

1. Kylin E. Studien ber das Hypertonie-Hyperglyk, mie-Hyperurik, miesyndrom. Zentrabl f innere Med Leipz 1923, 81:105-127.
2. Kaplan N.M. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989, 149:1514-1520.
3. DeFronzo R.A., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14:173-194.
4. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
5. Eckel R.H., Alberti K.G., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2010, 375:181-183.
6. Febbraio M.A. Role of interleukins in obesity: implications for metabolic disease. Trends Endocrinol Metab 2014, 25:312-319.
7. Cani P.D., Amar J., Iglesias M.A., Poggi M., Knauf C., Bastelica D., Neyrinck A.M., Fava F., Tuohy K.M., Chabo C., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
8. Vrieze A., Van Nood E., Holleman F., Salojarvi J., Kootte R.S., Bartelsman J.F., Dallinga-Thie G.M., Ackermans M.T., Serlie M.J., Oozeer R., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012, 143:913-916. e917.
9. Cox L.M., Blaser M.J. Pathways in microbe-induced obesity. Cell Metab 2013, 17:883-894.
10. Kashyap P.C., Marcobal A., Ursell L.K., Larauche M., Duboc H., Earle K.A., Sonnenburg E.D., Ferreyra J.A., Higginbottom S.K., Million M., et al. Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice. Gastroenterology 2013, 144:967-977.
11. Everard A., Cani P.D. Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol 2013, 27:73-83.
12. Zhao L. The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol 2013, 11:639-647.
13. Cani P.D., Geurts L., Matamoros S., Plovier H., Duparc T. Glucose metabolism: focus on gut microbiota, the endocannabinoid system and beyond. Diabetes Metab 2014, 40:246-257.
14. Le Chatelier E., Nielsen T., Qin J., Prifti E., Hildebrand F., Falony G., Almeida M., Arumugam M., Batto J.M., Kennedy S., et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013, 500:541-546.
15. Qin J., Li Y., Cai Z., Li S., Zhu J., Zhang F., Liang S., Zhang W., Guan Y., Shen D., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012, 490:55-60.
16. Zhang X., Shen D., Fang Z., Jie Z., Qiu X., Zhang C., Chen Y., Ji L. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS ONE 2013, 8:e71108.
17. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
18. Karlsson F.H., Tremaroli V., Nookaew I., Bergstrom G., Behre C.J., Fagerberg B., Nielsen J., Backhed F. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013, 498:99-103.
19. Firouzi S., Barakatun-Nisak M.Y., Ismail A., Majid H.A., Nor Azmi K. Role of probiotics in modulating glucose homeostasis: evidence from animal and human studies. Int J Food Sci Nutr 2013, 64:780-786.
20. Bernardeau M., Vernoux J.P. Overview of differences between microbial feed additives and probiotics for food regarding regulation, growth promotion effects and health properties and consequences for extrapolation of farm animal results to humans. Clin Microbiol Infect 2013, 19:321-330.
21. Delzenne N.M., Neyrinck A.M., Backhed F., Cani P.D. Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 2011, 7:639-646.
22. Drissi F., Merhej V., Angelakis E., El Kaoutari A., Carriere F., Henrissat B., Raoult D. Comparative genomics analysis of Lactobacillus species associated with weight gain or weight protection. Nutr Diabetes 2014, 4:e109.
23. Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H.J., Salminen S., et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014, 11:506-514.
24. Ben Salah R., Trabelsi I., Hamden K., Chouayekh H., Bejar S. Lactobacillus plantarum TN8 exhibits protective effects on lipid, hepatic and renal profiles in obese rat. Anaerobe 2013, 23:55-61.
25. Jung S.P., Lee K.M., Kang J.H., Yun S.I., Park H.O., Moon Y., Kim J.Y. Effect of Lactobacillus gasseri BNR17 on overweight and obese adults: a randomized, double-blind clinical trial. Korean J Fam Med 2013, 34:80-89.
26. Kadooka Y., Sato M., Ogawa A., Miyoshi M., Uenishi H., Ogawa H., Ikuyama K., Kagoshima M., Tsuchida T. Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial. Br J Nutr 2013, 110:1696-1703.
27. Kang J.H., Yun S.I., Park M.H., Park J.H., Jeong S.Y., Park H.O. Anti-obesity effect of Lactobacillus gasseri BNR17 in high-sucrose diet-induced obese mice. PLoS ONE 2013, 8:e54617.
28. Kondo S., Kamei A., Xiao J.Z., Iwatsuki K., Abe K. Bifidobacterium breve B-3 exerts metabolic syndrome-suppressing effects in the liver of diet-induced obese mice: a DNA microarray analysis. Benef Microbes 2013, 4:247-251.
29. Okubo T., Takemura N., Yoshida A., Sonoyama K. KK/Ta mice administered Lactobacillus plantarum strain no. 14 have lower adiposity and higher insulin sensitivity. Biosci Microbiota Food Health 2013, 32:93-100.
30. Park D.Y., Ahn Y.T., Park S.H., Huh C.S., Yoo S.R., Yu R., Sung M.K., McGregor R.A., Choi M.S. Supplementation of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 in diet-induced obese mice is associated with gut microbial changes and reduction in obesity. PLoS ONE 2013, 8:e59470.
31. Poutahidis T., Kleinewietfeld M., Smillie C., Levkovich T., Perrotta A., Bhela S., Varian B.J., Ibrahim Y.M., Lakritz J.R., Kearney S.M., et al. Microbial reprogramming inhibits Western diet-associated obesity. PLoS ONE 2013, 8:e68596.
32. Sakai T., Taki T., Nakamoto A., Shuto E., Tsutsumi R., Toshimitsu T., Makino S., Ikegami S. Lactobacillus plantarum OLL2712 regulates glucose metabolism in C57BL/6 mice fed a high-fat diet. J Nutr Sci Vitaminol (Tokyo) 2013, 59:144-147.
33. Yadav H., Lee J.H., Lloyd J., Walter P., Rane S.G. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem 2013, 288:25088-25097.
34. Yoo S.R., Kim Y.J., Park D.Y., Jung U.J., Jeon S.M., Ahn Y.T., Huh C.S., McGregor R., Choi M.S. Probiotics L. plantarum and L. curvatus in combination alter hepatic lipid metabolism and suppress diet-induced obesity. Obesity (Silver Spring) 2013, 21:2571-2578.
35. Karlsson Videhult F., Ohlund I., Stenlund H., Hernell O., West C.E. Probiotics during weaning: a follow-up study on effects on body composition and metabolic markers at school age. Eur J Nutr 2014, [Epub ahead of print].
36. Lindsay K.L., Kennelly M., Culliton M., Smith T., Maguire O.C., Shanahan F., Brennan L., McAuliffe F.M. Probiotics in obese pregnancy do not reduce maternal fasting glucose: a double-blind, placebo-controlled, randomized trial (Probiotics in Pregnancy Study). Am J Clin Nutr 2014, 99:1432-1439.
37. Miyoshi M., Ogawa A., Higurashi S., Kadooka Y. Anti-obesity effect of Lactobacillus gasseri SBT2055 accompanied by inhibition of pro-inflammatory gene expression in the visceral adipose tissue in diet-induced obese mice. Eur J Nutr 2014, 53:599-606.
38. Moya-Perez A., Romo-Vaquero M., Tomas-Barberan F., Sanz Y., Garcia-Conesa M.T. Hepatic molecular responses to Bifidobacterium pseudocatenulatum CECT 7765 in a mouse model of diet-induced obesity. Nutr Metab Cardiovasc Dis 2014, 24:57-64.
39. Ogawa A., Kadooka Y., Kato K., Shirouchi B., Sato M. Lactobacillus gasseri SBT2055 reduces postprandial and fasting serum non-esterified fatty acid levels in Japanese hypertriacylglycerolemic subjects. Lipids Health Dis 2014, 13:36.
40. Park J.E., Oh S.H., Cha Y.S. Lactobacillus plantarum LG42 isolated from gajami sik-hae decreases body and fat pad weights in diet-induced obese mice. J Appl Microbiol 2014, 116:145-156.
41. Plaza-Diaz J., Gomez-Llorente C., Abadia-Molina F., Saez-Lara M.J., Campana-Martin L., Munoz-Quezada S., Romero F., Gil A., Fontana L. Effects of Lactobacillus paracasei CNCM I-4034, Bifidobacterium breve CNCM I-4035 and Lactobacillus rhamnosus CNCM I-4036 on hepatic steatosis in Zucker rats. PLoS ONE 2014, 9:e98401.
42. Reichold A., Brenner S.A., Spruss A., Forster-Fromme K., Bergheim I., Bischoff S.C. Bifidobacterium adolescentis protects from the development of nonalcoholic steatohepatitis in a mouse model. J Nutr Biochem 2014, 25:118-125.
43. Ritze Y., Bardos G., Claus A., Ehrmann V., Bergheim I., Schwiertz A., Bischoff S.C. Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PLoS ONE 2014, 9:e80169.
44. Sanchez M., Darimont C., Drapeau V., Emady-Azar S., Lepage M., Rezzonico E., Ngom-Bru C., Berger B., Philippe L., Ammon-Zuffrey C., et al. Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women. Br J Nutr 2014, 111:1507-1519.
45. Toral M., Gomez-Guzman M., Jimenez R., Romero M., Sanchez M., Utrilla M.P., Garrido-Mesa N., Rodriguez-Cabezas M.E., Olivares M., Galvez J., et al. The probiotic Lactobacillus coryniformis CECT5711 reduces the vascular pro-oxidant and pro-inflammatory status in obese mice. Clin Sci (Lond) 2014, 127:33-45.
46. Wang J., Tang H., Zhang C., Zhao Y., Derrien M., Rocher E., van-Hylckama Vlieg J.E., Strissel K., Zhao L., Obin M., et al. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J 2014, [Epub ahead of print]. 10.1038/ismej.2014.99.
47. McFarland L.V. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010, 16:2202-2222.
48. Everard A., Matamoros S., Geurts L., Delzenne N.M., Cani P.D. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. MBio 2014, 5:e01011-e01014.
49. Thomas C., Gioiello A., Noriega L., Strehle A., Oury J., Rizzo G., Macchiarulo A., Yamamoto H., Mataki C., Pruzanski M., et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009, 10:167-177.
50. Watanabe M., Houten S.M., Mataki C., Christoffolete M.A., Kim B.W., Sato H., Messaddeq N., Harney J.W., Ezaki O., Kodama T., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006, 439:484-489.
51. Li F., Jiang C., Krausz K.W., Li Y., Albert I., Hao H., Fabre K.M., Mitchell J.B., Patterson A.D., Gonzalez F.J. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 2013, 4:2384.
52. Sayin S.I., Wahlstrom A., Felin J., Jantti S., Marschall H.U., Bamberg K., Angelin B., Hyotylainen T., Oresic M., Backhed F. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013, 17:225-235.
53. Degirolamo C., Rainaldi S., Bovenga F., Murzilli S., Moschetta A. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep 2014, 7:12-18.
54. Joyce S.A., MacSharry J., Casey P.G., Kinsella M., Murphy E.F., Shanahan F., Hill C., Gahan C.G. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci USA 2014, 111:7421-7426.
55. Begley M., Hill C., Gahan C.G. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol 2006, 72:1729-1738.
56. Fei N., Zhao L. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. ISME J 2013, 7:880-884.
57. Zhang H., DiBaise J.K., Zuccolo A., Kudrna D., Braidotti M., Yu Y., Parameswaran P., Crowell M.D., Wing R., Rittmann B.E., et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA 2009, 106:2365-2370.
58. Everard A., Belzer C., Geurts L., Ouwerkerk J.P., Druart C., Bindels L.B., Guiot Y., Derrien M., Muccioli G.G., Delzenne N.M., et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013, 110:9066-9071.
59. Karlsson C.L., Onnerfalt J., Xu J., Molin G., Ahrne S., Thorngren-Jerneck K. The microbiota of the gut in preschool children with normal and excessive body weight. Obesity (Silver Spring) 2012, 20:2257-2261.
60. Everard A., Lazarevic V., Derrien M., Girard M., Muccioli G.M., Neyrinck A.M., Possemiers S., Van H.A., Francois P., de Vos W.M., et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 2011, 60:2775-2786.
61. Hansen K.B., Rosenkilde M.M., Knop F.K., Wellner N., Diep T.A., Rehfeld J.F., Andersen U.B., Holst J.J., Hansen H.S. 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. J Clin Endocrinol Metab 2011, 96:E1409-E1417.
62. Kimura I., Ozawa K., Inoue D., Imamura T., Kimura K., Maeda T., Terasawa K., Kashihara D., Hirano K., Tani T., et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun 2013, 4:1829.
63. Kimura I., Inoue D., Hirano K., Tsujimoto G. The SCFA receptor GPR43 and energy metabolism. Front Endocrinol (Lausanne) 2014, 5:85.
64. Shin N.R., Lee J.C., Lee H.Y., Kim M.S., Whon T.W., Lee M.S., Bae J.W. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 2014, 63:727-735.
65. Kim S.W., Park K.Y., Kim B., Kim E., Hyun C.K. Lactobacillus rhamnosus GG improves insulin sensitivity and reduces adiposity in high-fat diet-fed mice through enhancement of adiponectin production. Biochem Biophys Res Commun 2013, 431:258-263.